BioCatalystWatch
MDGLWorkspace / MDGL / OverviewCompany library
MADRIGAL PHARMACEUTICALS, INC. logo

MADRIGAL PHARMACEUTICALS, INC.

MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Website

Price
Market cap
Next catalystExpected Q4 2026Ervogastat/resmetirom — planned Phase 2 combination trial · Regulatory meetingSEC filing ↗
Cash

Chart & Events

Candle interval

Core Clinical

Rezdiffra (resmetirom)

THR-β

PreINDP1P2FilingApproved
Upcoming / outlook

  • Timing and evidence

Ervogastat/resmetirom

DGAT-2 + THR-β

PreINDP1P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

Ervogastat/resmetirom

DGAT-2 + THR-β

PreINDP1P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Rezdiffra (resmetirom)

THR-β

PreINDP1P2FilingApproved
Upcoming / outlook

  • Timing and evidence

Other pipelines

GLP-1 receptor

PreINDP1P2P3FilingApproved

PNPLA3 (MGL-0795 component)

Approved / commercial

Rezdiffra (resmetirom)

THR-β

PreINDP1P2P3FilingApproved
Upcoming / outlook

History / paused

PNPLA3

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

MDGL PR & News

PR & News

MDGL SEC archive